Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$23.17 USD
+0.21 (0.92%)
Updated Aug 4, 2025 03:04 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NKTR 23.17 +0.21(0.92%)
Will NKTR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Other News for NKTR
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After ...
Nektar gets FDA fast track status for alopecia areata drug
Nektar (NKTR) Gains FDA Fast Track Status for Alopecia Areata Treatment
Nektar's rezpegaldesleukin granted Fast Track Designation in alopecia areata
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of ...